Debevoise & Plimpton LLP advises Canada Pension Plan Investment Board (CPP Investments) as one of the investors in the $700 million capital raise by Sana Biotechnology Inc., a biotech company focused on engineering cells as medicines for patients. For more information on the completion of the initial financing, see Sana’s press release here.
CPP Investments is a professional investment management organization that invests around the world in the best interests of the more than 20 million contributors and beneficiaries of the Canada Pension Plan. Sana Biotechnology is focused on creating and delivering engineered cells as medicines for patients.
The Debevoise team is led by M&A partner Kevin Schmidt and includes M&A associates Matthew Delja and Milan Udawatta, FDA regulatory partner Paul Rubin intellectual property partner Henry Lebowitz and tax associate Gregory Arutiunov.